TY - JOUR
T1 - Vaccination strategies in follicular lymphoma
AU - Kannan, Shibichakravarthy
AU - Neelapu, Sattva S.
N1 - Funding Information:
This trial was initiated by the National Cancer Institute, National Institutes of Health (Bethesda, MD) and later sponsored by Biovest International, Inc. (Worcester, MA) [24••]. The study design was very similar to that of the
PY - 2009
Y1 - 2009
N2 - Follicular lymphoma is one of the most immuneresponsive cancers. The clonal tumor immunoglobulin expressed on the surface of malignant B cells, termed idiotype, has been used as a tumor-specific antigen in therapeutic vaccination strategies for follicular lymphoma and other B-cell malignancies. A number of phase 1 and phase 2 clinical trials have established the safety and immunogenicity of idiotype vaccine in follicular lymphoma. Three randomized, double-blind, controlled phase 3 clinical trials have recently been completed to definitively evaluate the clinical benefit of idiotype vaccine in follicular lymphoma. This review focuses on the results of these idiotype vaccine trials and discusses poten tial strategies to enhance the efficacy of vaccines in the future.
AB - Follicular lymphoma is one of the most immuneresponsive cancers. The clonal tumor immunoglobulin expressed on the surface of malignant B cells, termed idiotype, has been used as a tumor-specific antigen in therapeutic vaccination strategies for follicular lymphoma and other B-cell malignancies. A number of phase 1 and phase 2 clinical trials have established the safety and immunogenicity of idiotype vaccine in follicular lymphoma. Three randomized, double-blind, controlled phase 3 clinical trials have recently been completed to definitively evaluate the clinical benefit of idiotype vaccine in follicular lymphoma. This review focuses on the results of these idiotype vaccine trials and discusses poten tial strategies to enhance the efficacy of vaccines in the future.
UR - http://www.scopus.com/inward/record.url?scp=70349754495&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70349754495&partnerID=8YFLogxK
U2 - 10.1007/s11899-009-0025-2
DO - 10.1007/s11899-009-0025-2
M3 - Review article
C2 - 20425407
AN - SCOPUS:70349754495
SN - 1558-8211
VL - 4
SP - 189
EP - 195
JO - Current hematologic malignancy reports
JF - Current hematologic malignancy reports
IS - 4
ER -